Immucell Corp
ICCC- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000811641
No open-market purchases or sales by Immucell Corp insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.4M in total; no superinvestor holds it.
13F holders, Q4 2022
Institutional positions in Immucell Corp as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 26
- 0 vs. Q3 2022
- Shares held
- 982.1K
- +10.7K (+1.1%) vs. Q3 2022
- Total value
- $5.41M
- −$1.86M (−25.6%) vs. Q3 2022
- New holders
- 1
- 5 more added
- Sold out
- 1
- 5 more reduced
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ICCC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 31 | $13.4M |
| Q1 2026 | 27 | $8.67M |
| Q4 2025 | 26 | $7.87M |
| Q3 2025 | 27 | $8.08M |
| Q2 2025 | 25 | $9.00M |
| Q1 2025 | 27 | $5.79M |
| Q4 2024 | 27 | $6.21M |
| Q3 2024 | 22 | $4.27M |
| Q2 2024 | 28 | $5.56M |
| Q1 2024 | 25 | $5.39M |
| Q4 2023 | 28 | $5.31M |
| Q3 2023 | 30 | $5.47M |
| Q2 2023 | 31 | $5.32M |
| Q1 2023 | 30 | $5.42M |
| Q4 2022 | 26 | $5.41M |
| Q3 2022 | 26 | $7.26M |
| Q2 2022 | 29 | $8.53M |
| Q1 2022 | 27 | $9.18M |
| Q4 2021 | 29 | $7.04M |
| Q3 2021 | 28 | $8.05M |
| Q2 2021 | 28 | $7.45M |
| Q1 2021 | 28 | $7.20M |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Immucell Corp; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 206,325 | $1.26M | 0.00% | +3,596+1.8% | Added |
| Renaissance Technologies LLC | 125,489 | $765.0K | 0.00% | −12,097−8.8% | Reduced |
| Bleichroeder LP | 101,594 | $619.7K | 0.13% | 00.0% | Unchanged |
| Morgan Stanley | 76,874 | $468.9K | 0.00% | +2,800+3.8% | Added |
| Dimensional Fund Advisors LP | 62,170 | $381.0K | 0.00% | +39,591+175.3% | Added |
| Shufro Rose & Co LLC | 62,408 | $380.7K | 0.03% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 38,082 | $233.0K | 0.00% | −53−0.1% | Reduced |
| Overbrook Management Corp | 35,532 | $216.7K | 0.06% | 00.0% | Unchanged |
| Strategic Financial Services, Inc, | 31,000 | $189.7K | 0.02% | 00.0% | Unchanged |
| Perritt Capital Management Inc | 30,000 | $183.0K | 0.10% | −6,494−17.8% | Reduced |
| HighTower Advisors, LLC | 21,354 | $131.0K | 0.00% | 00.0% | Unchanged |
| Wealth Effects LLC | 15,650 | $95.5K | 0.05% | 00.0% | Unchanged |
| BlackRock Inc. | 15,596 | $95.1K | 0.00% | +324+2.1% | Added |
| Flagship Harbor Advisors, LLC | 14,230 | $86.8K | 0.01% | −2,000−12.3% | Reduced |
| Northern Trust Corp | 12,445 | $75.9K | 0.00% | −222−1.8% | Reduced |
| Minerva Advisors LLC | 11,958 | $72.1K | 0.05% | 00.0% | Unchanged |
| Essex Financial Services, Inc. | 11,000 | $67.0K | 0.01% | 00.0% | Unchanged |
| HM Payson & Co | 8,130 | $49.8K | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 2,038 | $12.4K | 0.00% | +6+0.3% | Added |
| UBS Group AG | 1,500 | $9.15K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 1,276 | $8.00K | 0.00% | +1,276 | New |
| US Bancorp | 600 | $3.66K | 0.00% | 00.0% | Unchanged |
| Geneos Wealth Management Inc. | 244 | $1.49K | 0.00% | 00.0% | Unchanged |
| Northwestern Mutual Wealth Management Co | 152 | $927 | 0.00% | 00.0% | Unchanged |
| Cresset Asset Management, LLC | 96,426 | $721 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 37 | $226 | 0.00% | 00.0% | Unchanged |
| Prosperity Planning, Inc. | 0 | $0 | 0.00% | −16,000−100.0% | Sold out |